Výsledky vyhledávání - "Advanced solid tumours"

Akademický článek

A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours

Autor: Yvonne L. E. Ang, Gwo Fuang Ho, Ross A. Soo, Raghav Sundar, Sing Huang Tan, Wei Peng Yong, Samuel G. W. Ow, Joline S. J. Lim, Wan Qin Chong, Phyu Pyar Soe, Bee Choo Tai, Lingzhi Wang, Boon Cher Goh, Soo-Chin Lee

Publikováno v: BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)

Abstract Background We previously reported that low-dose, short-course sunitinib prior to neoadjuvant doxorubicin-cyclophosphamide (AC) normalised tumour vasculature and improved perfusion, but resulted in neutropenia and delayed subsequent cycles in

Externí odkaz: https://doaj.org/article/64ad21aacf0e4e9dbb97e7c6812136d7

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Anterior Intratumoural Chemotherapy: A Newer Modality of Treatment in Advanced Solid Tumours in Children

Autor: A.N. Gangopadhyay, Rahi Rajeev, S.P. Sharma, Vijai D. Upadhyaya, N.C. Arya, Vijayendra Kumar, S.C. Gopal

Publikováno v: Asian Journal of Surgery, Vol 31, Iss 4, Pp 225-229 (2008)

Advanced and inoperable solid tumours in children have high mortality despite aggressive multimodal treatment. Intravenous chemotherapy is abandoned at times because of systemic toxicity. This study investigated intratumoural chemotherapy and compare

Externí odkaz: https://doaj.org/article/f97f5abcc65d468e89a4190dab0d1eb3

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Subgroup analyses in randomized phase III trials of systemic treatments in patients with advanced solid tumours: a systematic review of trials published between 2017 and 2020

Autor: C. Paratore, C. Zichi, M. Audisio, M. Bungaro, A. Caglio, R. Di Liello, T. Gamba, P. Gargiulo, A. Mariniello, M.L. Reale, F. Perrone, M. Di Maio

Publikováno v: ESMO Open. 7:100593

Subgroup analyses of randomized controlled trials are very common in oncology; nevertheless, the methodological approach has not been systematically evaluated. The present analysis was conducted with the aim of describing the prevalence and methodolo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fa84e418885ff9091410bf9934d4b93
https://doi.org/10.1016/j.esmoop.2022.100593

Zobrazit plný text záznamu

A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours

Autor: Lingzhi Wang, Gwo Fuang Ho, Yvonne Ang, Soo-Chin Lee, Bee Choo Tai, Ross A. Soo, Samuel Guan Wei Ow, Joline S.J. Lim, Sing Huang Tan, Wan Qin Chong, Boon Cher Goh, Raghav Sundar, Phyu Pyar Soe, Wei Peng Yong

Publikováno v: BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
BMC Cancer

BackgroundWe previously reported that low-dose, short-course sunitinib prior to neoadjuvant doxorubicin-cyclophosphamide (AC) normalised tumour vasculature and improved perfusion, but resulted in neutropenia and delayed subsequent cycles in breast ca

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a73a38445a06aef1681dd2120158331
https://doi.org/10.1186/s12885-020-07616-4

Zobrazit plný text záznamu

Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment

Autor: Christian Rolfo, L Rhoda Molife, Jean-Yves Blay, Alain Ravaud, Katerina Kopeckova, Rebecca Kristeleit, Antoine Italiano, Jan H.M. Schellens, Nicolas Isambert, Judith de Vos-Geelen, Wendy Bannister, Regina Demlová, Maria Learoyd, Myung-Ah Lee, Gershon Y. Locker, Olivier Rosmorduc, Thomas Decaens

Publikováno v: British Journal of Clinical Pharmacology, 86(9), 1807-1818. Wiley
Br J Clin Pharmacol

Aims Olaparib, a potent oral poly(ADP-ribose) polymerase inhibitor, is partially hepatically cleared. We investigated the pharmacokinetics (PK) and safety of olaparib in patients with mild or moderate hepatic impairment to provide dosing recommendati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f8942641984e913e81ebca1eb66171e
https://cris.maastrichtuniversity.nl/en/publications/3f6c882d-a88f-4c5a-92ca-fde001eb9f0b

Zobrazit plný text záznamu

Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment

Autor: Rolfo, Christian, de Vos-Geelen, Judith, Isambert, Nicolas, Molife, L Rhoda, Schellens, Jan H M, De Grève, Jacques, Dirix, Luc, Grundtvig-Sørensen, Peter, Jerusalem, Guy, Leunen, Karin, Mau-Sørensen, Morten, Plummer, Ruth, Learoyd, Maria, Bannister, Wendy, Fielding, Anitra, Ravaud, Alain, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology

Publikováno v: Clinical Pharmacokinetics, 58(9), 1165-1174. Adis International Ltd
Clinical Pharmacokinetics, 58(9), 1165. Adis International Ltd

BACKGROUND: Olaparib, a potent oral poly(ADP-ribose) polymerase inhibitor, is partially renally cleared. We investigated the pharmacokinetics and safety of olaparib in patients with mild or moderate renal impairment to provide dosing recommendations.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0675a310cb6b40430804a775331f8fcc
https://pubmed.ncbi.nlm.nih.gov/30877569

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání